Welcome to our dedicated page for Solid Bioscience news (Ticker: SLDB), a resource for investors and traders seeking the latest updates and insights on Solid Bioscience stock.
Solid Biosciences Inc. develops precision genetic medicines for rare neuromuscular and cardiac diseases. The company’s recurring news centers on its gene therapy portfolio, including SGT-003 for Duchenne muscular dystrophy, SGT-212 for Friedreich’s ataxia, SGT-501 for catecholaminergic polymorphic ventricular tachycardia, and SGT-601 for TNNT2-mediated dilated cardiomyopathy.
Company updates also cover clinical data from Duchenne studies, regulatory designations for SGT-003, scientific presentations in gene and cell therapy, capital-raising activity, inducement equity grants, investor conference participation, shareholder voting matters, and governance disclosures.
Solid Biosciences reported Q1 2024 financial results and business updates, highlighting the Rare Pediatric Disease and Orphan Drug Designation for its Duchenne muscular dystrophy gene therapy candidate, SGT-003. The company plans to begin dosing in a Phase 1/2 trial in Q2 2024 with initial data expected by Q4 2024. Solid has entered a non-exclusive licensing agreement for its AAV-SLB101 capsid and maintains a strong cash position of $206.1 million, providing runway into 2026. R&D expenses decreased to $18.9 million due to prioritization of SGT-003, while net loss reduced to $24.3 million. Solid is advancing its diversified pipeline, including SGT-501 for CPVT, expected to file an IND in Q1 2025.
Solid Biosciences Inc. will present at the ASGCT 2024 Annual Meeting, showcasing advancements in AAV manufacturing, vector biology, and non-clinical data of their lead SGT-003 program. The presentations aim to highlight the company's commitment to developing genetic medicines for neuromuscular and cardiac diseases.
Solid Biosciences Inc. announced the issuance of 38,508 restricted stock units to two new employees under the 2024 Inducement Stock Incentive Plan. The RSUs will vest over four years subject to continued service with the company, in line with Nasdaq Listing Rule 5635(c)(4).
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.